Drug delivery companies, NanoMedical Systems and Leonardo Biosystems have inked a development deal wherein NanoMedical Systems will design and launch a commercial production process for nanoporous silicon particles used in the multi-stage drug delivery system of Leonardo Biosystems.
NanoMedical Systems and university scientists assisted Leonardo Biosystems to successfully produce prototype particles by exhibiting all the significant unit steps needed to produce the particles. Under the partnership, NanoMedical Systems will refine and combine all these processes to design a commercial process that allows Leonardo Biosystems for producing particles ideal for clinical studies.
NanoMedical Systems’ President and Chief Executive Officer, Randy Goodall stated that the company’s experience in the production of silicon-based uniquely-parallel nanofluidic structures for the advancement of its own drug delivery systems allows it to help Leonardo Biosystems to commercialize its production method.
Goodall further said that the NanoMedical Systems’ medical equipment engineering quality system is intended to develop an FDA-compliant process that will allow Leonardo Biosystems to perform clinical trials on its advanced drug delivery products.
Leonardo Biosystems’ Chief Executive Officer, Bruce D Given stated that the collaboration with NanoMedical Systems is based on its expertise in silicon materials and its ability to carry out the work under a quality system that complies with FDA. Development of a FDA-compliant commercial-scale production process is important for Leonardo Biosystems to convert its proof of concept data of its animal studies into clinical reality.
Source: http://www.leonardobiosystems.com